Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Actinium Pharmaceuticals (NYSE MKT: ATNM) and Axsome Therapeutics (NASDAQ: AXSM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGNResearch Report), Actinium Pharmaceuticals (ATNMResearch Report) and Axsome Therapeutics (AXSMResearch Report).

Actinium Pharmaceuticals (ATNM)

William Blair analyst Andy Hsieh reiterated a Buy rating on Actinium Pharmaceuticals on September 15. The company’s shares closed last Friday at $7.15.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 15.6% and a 48.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Vaccitech Plc, and Beyondspring.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $36.67 average price target, which is a 440.9% upside from current levels. In a report issued on September 15, JonesTrading also reiterated a Buy rating on the stock with a $40.00 price target.

Axsome Therapeutics (AXSM)

William Blair analyst Myles Minter reiterated a Buy rating on Axsome Therapeutics yesterday. The company’s shares closed last Friday at $28.88, close to its 52-week low of $19.38.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 19.7% and a 51.3% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Larimar Therapeutics.

Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $93.75, a 228.2% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $180.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.